KURA
Next earnings: Aug 6, 2026
Signal
Mixed11
Price
1
Move-5.34%Selling pressure
Volume
1
Volume1.0× avgNormal activity
Technical
1
RSIRSI 61Momentum positive
PRICE
Prev Close
9.74
Open
9.66
Day Range9.18 – 9.79
9.18
9.79
52W Range5.45 – 12.49
5.45
12.49
54% of range
VOLUME & SIZE
Avg Volume
1.4M
FUNDAMENTALS
P/E Ratio
-2.8x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.12
Market-like
Performance
1D
-5.34%
5D
-3.05%
1M
+3.13%
3M
+8.73%
6M
-17.75%
YTD
-11.26%
1Y
+53.16%
Best: 1Y (+53.16%)Worst: 6M (-17.75%)
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
revenue +5% YoY · 95% gross margin
Valuation
FAIR
P/E not available
Health
MODERATE
CR 6.1 · FCF negative
Bullish
Key MetricsTTM
Market Cap$818.50M
Revenue TTM$71.64M
Net Income TTM-$294.57M
Free Cash Flow-$84.46M
Gross Margin94.7%
Net Margin-411.2%
Operating Margin-443.5%
Return on Equity-142.0%
Return on Assets-45.1%
Debt / Equity0.13
Current Ratio6.15
EPS TTM$-3.32
Alpha SignalsFull Analysis →
What Moves This Stock

Ziftomenib Phase 2 clinical trial data readouts in NPM1-mutated and KMT2A-rearranged AML/ALL (complete response rates, overall survival, duration of response)

FDA regulatory interactions and potential breakthrough therapy designation or accelerated approval pathway discussions

Cash runway updates and equity financing announcements (dilution risk vs. funding security trade-off)

Partnership or licensing deal announcements with major pharma companies for development/commercialization rights

Macro Sensitivity
Economic Cycle

low - Clinical trial timelines and FDA regulatory processes are largely insulated from GDP fluctuations. However, severe recessions can impact: (1) ability to raise capital at attractive valuations, (2) pharma partnership activity as larger companies reduce business development spending, (3) patient enrollment if economic stress affects healthcare access. Cancer treatment demand is non-discretionary and recession-resistant.

Interest Rates

Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (DCF models for pre-revenue biotech are highly rate-sensitive). Higher rates also increase opportunity cost of capital, making speculative biotech less attractive vs. risk-free bonds. Financing costs rise modestly if company taps debt markets, though equity remains primary funding source. Rate environment significantly affects M&A valuations and partnership economics.

Key Risks

Clinical trial failure risk: Phase 2/3 trials have 30-40% historical success rates in oncology; negative efficacy or safety data could render pipeline worthless

Regulatory approval uncertainty: FDA may require additional trials, reject applications, or impose restrictive labels limiting commercial opportunity

Reimbursement pressure: Payers increasingly scrutinizing high-cost oncology drugs, potentially limiting pricing power even post-approval

Investor Profile

growth - High-risk, high-reward clinical-stage biotech attracts speculative growth investors and specialized healthcare funds willing to underwrite binary clinical trial outcomes. Investors seek 3-5x returns on successful drug approval but accept total loss risk on trial failure. Not suitable for value or income investors given negative earnings, no dividends, and uncertain commercialization timeline. Typical holders include biotech-focused hedge funds, venture capital, and retail investors with high risk tolerance.

Watch on Earnings
Ziftomenib Phase 2 complete response rates in NPM1-mutated R/R AML (benchmark: >40% CR rate needed for competitive profile)Cash and marketable securities balance (track quarterly burn rate and runway to next financing event)Clinical trial enrollment velocity and timeline adherence for pivotal studiesNasdaq Biotechnology Index (NBI) performance as proxy for sector sentiment and financing environment
Health Radar
3 strong3 concern
43/100
Liquidity
6.15Strong
Leverage
0.22Strong
Coverage
-296.1xConcern
ROE
-142.0%Concern
ROIC
-57.5%Concern
Cash
$149MStrong
ANALYST COVERAGE15 analysts
BUY
+133.2%upside to target
L $15.00
Med $21.50consensus
H $28.00
Buy
1493%
Hold
17%
14 Buy (93%)1 Hold (7%)0 Sell (0%)
Full report →
Stock Health
Composite Score
5 of 5 signals bullish
10/10
Technicals
RSI RangeRSI 61 — Bullish momentum
Volume
Volume FlowAccumulation — institutional buying
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 6.15 — healthy liquidity
Upcoming Events
EEarnings Report · After CloseMay 18, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 89 days
PDividend PaymentSep 9, 2026
In 115 days
Technicals
Technical SetupBULLISH
Technicals →

Trend

UptrendDeath Cross · 50D trails 200D by 1.5%

+6.0% vs SMA 50 · +4.4% vs SMA 200

Momentum

RSI60.9
Positive momentum, not extended
MACD+0.29
Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$12.49+35.5%
Current
$9.22
EMA 50
$8.92-3.2%
EMA 200
$8.51-7.7%
52W Low
$5.45-40.9%
52-Week RangeMid-range
$5.4554th %ile$12.49
Squeeze SetupVolume-based
Moderate Squeeze Setup

Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.

20-Day Money Flow
Acc days:3
Dist days:3
Edge:Even
Volume Context
Avg Vol (50D)1.4M
Recent Vol (5D)
1.8M+29%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 10 analysts
Analyst revisions:EPS↑ Revised UpRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$85.4M
$52.0M$144.8M
-$2.87
±16%
High9
FY2026(current)
$94.9M
$58.7M$224.7M
+11.1%-$3.57
±43%
High10
FY2027
$215.7M
$100.8M$555.3M
+127.3%-$2.64
±50%
High10
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryKURA
Last 8Q
-78.3%avg beat
Beat 4 of 8 quartersMissed 4 Estimates rising
+6%
Q3'24
+2%
Q4'24
+66%
Q1'25
-29%
Q2'25
-600%
Q3'25
-49%
Q4'25
-28%
Q1'26
+6%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
Powl Brian T.Chief Commerci…
$41K
Jan 27
SELL
Powl Brian T.Chief Commerci…
$13K
Jan 27
SELL
Ford KathleenCOO
$15K
Jan 27
SELL
Leoni MollieChief Medical …
$31K
Jan 27
SELL
Leoni MollieChief Medical …
$19K
Jan 27
SELL
Leoni MollieChief Medical …
$8K
Jan 27
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
BlackRock, Inc.
9.6M
2
SUVRETTA CAPITAL MANAGEMENT, LLC
8.6M
3
BVF INC/IL
8.4M
4
STATE STREET CORP
4.5M
5
ARMISTICE CAPITAL, LLC
3.7M
6
Prosight Management, LP
3.4M
7
Deep Track Capital, LP
2.6M
8
AQR CAPITAL MANAGEMENT LLC
2.1M
News & Activity

KURA News

About

at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Troy Wilson
Roger BakaleSenior Vice President of Manufacturing & Supply Chain
Troy Edward WilsonChairman, Chief Executive Officer & President
Greg MannSenior Vice President of Investor Relations & Corporate Affairs
PeersHealth Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
KURA
$9.22-5.34%$818M+2523.8%-41294.9%1500
$66.13-5.07%$13.0B+12626.1%-14525.8%1500
$94.92-3.79%$12.6B+3288.2%-4239.0%1500
$523.69-3.00%$12.1B+43205.3%-3008.0%1500
$227.72-1.96%$11.7B+6554.5%-2868.8%1500
$57.90-0.86%$11.2B50.3+1459.3%147.7%1500
$76.67-3.79%$10.8B+2325815.3%-19.7%1500
Sector avg-3.40%50.3+342210.4%-9401.2%1500